Bridget Doherty, MPH, MS, is a strategic policy, research, and communications professional with extensive experience in pharmaceuticals, medical devices, and healthcare publishing. Currently serving as the Director of Access and Policy Research at Johnson & Johnson Innovative Medicine, she develops and executes impactful policy research and scientific engagement plans aimed at developing an evidence-based understanding of U.S. healthcare policies’ impact on patients and the healthcare ecosystem. With a combined background of policy research and communications, Bridget specializes in translating complex concepts into actionable insights for diverse audiences.
Among her key contributions include the first comprehensive analysis of the FDA Accelerated Approval Program’s impact on patient outcomes in oncology, providing evidence that approximately 263,000 life years were gained for cancer patients. Bridget has published extensively on pivotal topics such as drug pricing policies and patient access, and she has led successful engagement strategies with advocacy and government relations partners. She also led global communications and public affairs for J&J’s Diabetes Device Unit. Prior to her career at Johnson & Johnson, Bridget served as Healthcare Policy Manager at GlaxoSmithKline, where she developed policy strategies to enhance patient access to care and improve health outcomes across various disease states. Before entering the pharmaceutical and medical device industries, Bridget had a 15-plus years career as a journalist and editor.
